Dermatological perspectives of malignant melanoma

Surgical Clinics of North America

Volumn 83, Issue 1, 2003, Pages 77-95

  Swetter, Susan M ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; EARLY DIAGNOSIS; HEALTH EDUCATION; HUMAN; MALIGNANT LENTIGO; MELANOCYTIC NEVUS; MELANOMA; PRECANCER; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; REVIEW; RISK FACTOR; SKIN BIOPSY; SKIN CARCINOGENESIS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET IRRADIATION;

DYSPLASTIC NEVUS SYNDROME; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MELANOMA; NEVUS, PIGMENTED; PRECANCEROUS CONDITIONS; RISK FACTORS; SKIN NEOPLASMS;

EID: 0037303765     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00091-9     Document Type: Review

References (113)

1. Jemal A, Thomas A, Murray T, et al. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Rigel DS. Melanoma update-2001. The Skin Cancer Foundation Journal 2001;19:13-4.
3. American Cancer Society. Cancer facts and figures. New York: American Cancer Society, Inc.; 2002.
4. Koh HK. Cutaneous melanoma. N Engl J Med 1992;325:171-82.
5. Kopf AW, Rigel DS, Freidman RJ. The rising incidence and mortality rate of malignant melanoma. J Dermatol Surg Oncol 1982;8:760-1.
6. Parker SL, Tong T, Boldern S, et al. Cancer statistics: 1996. CA Cancer J Clin 1996;46:5-27.
7. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 2000;50:215-36.
8. Berking C, Takemoto R, Satyamoorthy K, et al. Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol 2001;158:943-53.
9. Noonan FP, Recio JA, Takayama H, et al. Neonatal sunburn and melanoma in mice. Nature 2001;413:271-2.
10. Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001;44:837-46.
11. Lancaster HO, Nelson J. Sunlight as a cause of melanoma: a clinical survey. Med J Aust 1957;6:452-6.
12. Berwick M. Epidemiology: current trends, risk factors, and environmental concerns. In: Balch CM, Houghton AN, Sober AJ, et al, editors. Cutaneous melanoma. 3rd edition. St Louis: Quality Medical Publishing; 1998. p. 551-71.
13. Burton RC. Malignant melanoma in the year 2000. CA Cancer J Clin 2000;50:209-13.
14. Giles GG, Armstrong BK, Burton RC, et al. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994. BMJ 1996;312:1121-5.
15. Nguyen HL, Armstrong B, Coates M. Cutaneous melanoma in NSW in 1983 to 1995. Sydney: New South Wales Cancer Council; 1997.
16. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer 1998;78:144-8.
17. Kraemer KH, Lee MM, Andrews AD, et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994;130:1018-21.
18. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum-cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241-50.
19. Gallagher RP, McLean DI, Yang CP, et al. Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Arch Dermatol 1990;126:770-6.
20. Kelly JW, Rivers JK, MacLennan R, et al. Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol 1994;30:40-8.
21. Pope DJ, Sorahan R, Marsden JR, et al. Benign pigmented nevi in children: prevalence and associated factors: the West Midlands, United Kingdom mole study. Arch Dermatol 1992;128:1201-6.
22. Breitbart M, Garbe C, Buttner P, et al. Ultraviolet light exposure, pigmentary traints and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry. Acta Derm Venereol 1997;77:374-8.
23. Harrison SL, MacLennan R, Speare R, et al. Sun exposure and melanocytic naevi in young Australian children. Lancet 1994;344:1529-32.
24. Luther H, Altmeyer P, Garbe C, et al. Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol 1996;32:1473-8.
25. Richard MA, Grob JJ, Gouvernet J, et al. Role of sun exposure on nevus. First study in age-sex phenotype-controlled populations. Arch Dermatol 1993;129:1280-5.
26. Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990;66:387-95.
27. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459-68.
28. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277:1439-44.
29. Gallagher RP, Rivers JK, Lee TK, et al. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. JAMA 2000;283:2955-60.
30. Rhodes AR, Weinstock MA, Fitzpatrick TB, et al. Risk factors for cutaneous melanoma - a practical method of recognizing predisposed individuals. JAMA 1987;258:3146-54.
31. English DR, Armstrong BK, Kricker A, et al. Sunlight and cancer. Cancer Causes Control 1997;8:271-83.
32. Evans RD, Kopf AW, Lew RA, et al. Risk factors for the development of malignant melanoma - I. Review of case-control studies. J Dermatol Surg Oncol 1988;14:393-407.
33. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61.
34. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 1997;336:1041-5.
35. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br. J Dermatol 1999;141:108-12.
36. Bower CP, Lear JR, Bygrave S, et al. Basal cell carcinoma and risk of subsequent malignancies: a cancer registry-based study in southwest England. J Am Acad Dermatol 2000;42:988-91.
37. Friedman GD, Tekawa IS. Association of basal cell skin cancers with other cancers (United States). Cancer Causes Control 2000;11:891-7.
38. Swetter SM. Malignant melanoma from the dermatologic perspective. Surg Clin N Am 1996;76:1287-98.
39. Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol 1993;100:3225-55.
40. Stolz W, Schmoeckel C, Landthaler M, et al. Association of early malignant melanoma with nevocytic nevi. Cancer 1989;63:550-5.
41. Williams ML, Sagebiel RW. Melanoma risk factors and atypical moles. West J Med 1994;160:343-50.
42. Walton RG, Jacobs AH, Cox AJ. Pigmented lesions in newborn infants. Br J Dermatol 1976;95:389-96.
43. Castilla EE, de Graca M, Orioli-Parreiras IM. Epidemiology of congenital pigmented naevi. Naevi: I. Incidence rates and relative frequencies. Br J Dermatol 1981;104:307-15.
44. Ceballos PI, Ruiz-Maldonado R, Mihm MC. Melanoma in children. N Engl J Med 1995;332:656-62.
45. Kopf AW, Bart RS, Hennessey P. Congenital nevocytic nevi and malignant melanomas. J Am Acad Dermatol 1979;1:123-30.
46. Lorentzen M, Pers M, Bretteville-Jensen G. The incidence of malignant transformation in giant pigmented nevi. Scand J Plast Reconstr Surg 1977;11:163-7.
47. Rhodes AR, Wood WC, Sober AJ, et al. Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg 1981;67:782-90.
48. Roth ME, Grant-Kels JM, Kuhn K, et al. Melanoma in children. J Am Acad Dermatol 1990;22:265-74.
49. Williams ML, Pennella R. Melanoma, melanocytic nevi, and other melanoma risk factors in children. J Pediatr 1994;124:833-45.
50. Gari LM, Rivers JK, Kopf AW. Melanomas arising in large congenital nevocytic nevi: a prospective study. Dermatology 1988;5:151-8.
51. Kaplan EN. The risk of malignancy in large congenital nevi. Plast Reconstr Surg 1974;53:421-8.
52. Ruiz-Maldonado R, Tamayo L, Laterza AM, et al. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992;120:906-11.
53. Trozak DJ, Rowland WD, Hu F. Metastatic malignant melanoma in prepubertal children. Pediatrics 1975;55:191.
54. DeDavid M, Orlow SJ, Provost N, et al. Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol 1996;35:529-38.
55. Frieden IF, Williams ML, Barkovich AJ. Giant congential melanocytic nevi: brain magnetic resonance findings in neurologically asymptomatic children. J Am Acad Dermatol 1994;31:423-9.
56. Ruiz-Maldonado R, Orozco-Covarrubias ML. Malignant melanoma in children. Arch Dermatol 1997;133:363-71.
57. Orlow SJ. Melanomas in children. Pediatr Rev 1995;16:365-9.
58. Rhodes AR, Melski JW. Small congenital nevocellular nevi and the risk of cutnaeous melanoma. J Pediatr 1982;100:219-24.
59. Rhodes AR, Sober AJ, Day CL Jr, et al. The malignant potential of small congenital nevocellular nevi. An estimate of association based on a histologic study of 234 primary cutaneous melanomas. J Am Acad Dermatol 1982;6:230-41.
60. Sahin S, Levine L, Kopf AW, et al. Risk of melanoma in medium-sized congenital melanocytic nevi: a follow-up study. J Am Acad Dermatol 1998;39:428-33.
61. Swerdlow AJ, English JSC, Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995;32:595-9.
62. Illig L, Weidner F, Hundeiker M. Congenital nevi ≤10 cm as precursors to melanoma: 52 cases, a review, and a new concept. Arch Dermatol 1985;121:1274-81.
63. Bataille V, Bishop JA, Sasieni P, et al. Risks of cutaneous melanoma in relation to the numbers, types, and sites of naevi: a case-control study. Br J Cancer 1996;73:1605-11.
64. MacKie RM, English J, Aitchison TC, et al. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 1985;113:167-74.
65. Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions "the B-K mole syndrome." Arch Dermatol 1978;114:732-8.
66. Greene MH, Clark WH Jr, Tucker MA, et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65.
67. Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978;15:352-6.
68. Kraemer KH, Greene MH, Tarone R, et al. Dysplastic naevi and cutaneous melanoma risk. Lancet 1983;2:1076-7.
69. Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985;45:1855-61.
70. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi: markers for increased risk for melanoma. Cancer 1989;63:386-9.
71. Kang S, Barnhill RL, Mihm MC, et al. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994;130:999-1001.
72. Slade J, Marghoob AA, Salopek TG, et al. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995;32:479-94.
73. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993;341:1618-20.
74. Lever WF, Schaumberg-Lever G. In: Histopathology of the skin. 7th edition. New York: JB Lippincott; 1990. p. 756-805.
75. Clark WH Jr, Elder DE, Guery D, IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
76. U.S. Dept. of Health and Human Services, Public Health Service. NIH consensus development conference on diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.
77. Langley RG, Fitzpatrick TB, Sober AJ. Clinical characteristics. In: Balch CM, Houghton AN, Sober AJ, et al, editors. Cutaneous melanoma. 3rd edition. St Louis: Quality Medical Publishing; 1998. p. 81-101.
78. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987;116:303-10.
79. Reintgen DS, McCarty KM Jr, Cox E, et al. Malignant melanoma in black American and white American populations. A comparative review. JAMA 1982;248:1856-9.
80. Swetter SM. Malignant melanoma. eMedicine Journal [serial online] 2002. Available at: http://www.emedicine.com/derm/topic257.htm.
81. Kelemen PR, Essner R, Foshag LJ, et al. Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma. J Am Coll Surg 1999;189:247-52.
82. Friedman RJ, Rigel DS, Silverman MK, et al. Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin. CA Cancer J Clin 1991;41:201-6.
83. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993;3:395-401.
84. Martin RH. Relationship between risk factors, knowledge and preventive behaviour relevant to skin cancer in general practice patients in south Australia. Br J Gen Pract 1995;45:365-7.
85. Hall HI, Miller DR, Rogers JD, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999;40:35-42.
86. Chuang TY, Charles J, Reizner GT, et al. melanoma in Kauai, Hawaii, 1981-1900: the significance of in situ melanoma and the incidence trend. Int J Dermatol 1999;38:101-7.
87. Rigel DS, Naylor M, Robinson JK. What is the evidence for a sunscreen and melanoma controversy? Arch Dermatol 2000;136:1447-9.
88. American Academy of Pediatrics. Ultraviolet light: a hazard to children. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1999;104:328-33.
89. American Academy of Dermatology. 2002 melanoma/skin cancer screening program. Schaumburg (IL): 2002.
90. McDonald CJ. American Cancer Society perspective on the American College of Preventive Medicine's policy statements on skin cancer prevention and screening. CA Cancer J Clin 1998;48:232-5.
91. U.S. Preventive Services Task Force. Screening for skin cancer: recommendations and rationale. Am J Prev Med 2001;20(3S):44-6.
92. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd edition. Washington, DC: Office of Disease Prevention and Health Promotion, U.S. Government Printing Office; 1996.
93. deRooij MJ, Rampen FH, Schouten LJ, et al. Volunteer melanoma screenings. Follow-up, compliance, and outcome. Dermatol Surg 1997;23:197-201.
94. deRooij MJ, Rampen FH, Schouten LF, et al. Skin cancer screening focusing on melanoma yields more selective attendance. Arch Dermatol 1995;131:422-5.
95. Katris P, Donovan RJ, Gray BN. The use of targeted and non-targeted advertising to enrich skin cancer screening samples. Br J Dermatol 1996;135:268-74.
96. Geller AC, Sober AJ, Zhang Z, et al. Strategies for improving improving melanoma education and screening for men > or = 50 years: findings of the American Academy of Dermatological National Skin Cancer Screening Program. Cancer 2002;95:1554-61.
97. Ascierto PA, Satriano RA, Palmiere G, et al. Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma. Melanoma Res 1998;8:529-37.
98. Soyer HP, Kenet RO, Wolf IH, et al. Clinicopathologic correlation of pigmented skin lesions using dermoscopy. Eur J Dermatol 2000;10:22-8.
99. Binder M, Kittler H, Seeber A, et al. Epiluminescence microscopy-based classification of pigmented skin lesions using computerized image analysis and an artificial neural network. Melanoma Res 1998;8:261-6.
100. Menzies SW. Automated epiluminescence microsopy: human vs machine in the diagnosis of melanoma. Arch Dermatol 1999;135:1538-40.
101. Gammal S, Hartwig R, Aygen S, et al. Improved resolution of magnetic resonance microscopy in examination of skin tumors. J Invest Dermatol 1995;106:1287-92.
102. Semple JL, Gupta AK, From L, et al. Does high-frequency (40-60 MHz) ultrasound imaging play a role in the clinical management of cutaneous melanoma? Ann Plast Surg 1995;34:599-605.
103. Busam KF, Hester K, Charles C, et al. Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. Arch Dermatol 2001;137:923-9.
104. Langley RG, Rajadhyasksha M, Dwyer PJ, et al. Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo. J Am Acad Dermatol 2001;45:365-76.
105. Casselith BR, Clark WH Jr, Lusk EJ, et al. How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol 1986;14:555-60.
106. Federman DG, Hogan D, Taylor JR, et al. A comparison of diagnosis, evaluation, and treatment of patients with dermatologic disorders. J Am Acad Dermatol 1995;32:726-9.
107. Stern RS, Boudreau C, Arndt KA. Diagnostic accuracy and appropriateness of care for seborrheic keratoses. JAMA 1991;265:74-7.
108. Wagner RF Jr, Wagner D, Tomich JM, et al. Diagnoses of skin disease: dermatologists vs. nondermatologists. J Dermatol Surg Oncol 1985;11:476-9.
109. Roush GC, Barnhill RL, Duray PH, et al. Diagnosis of the dysplastic nevus in different populations. J Am Acad Dermatol 1986;14:393-407.
110. Greene MH, Young J, Clark WH Jr. Malignant melanoma in renal-transplant recipients. Lancet 1981;1:1196-9.
111. Halpern AC, Guerry D, Elder DE, et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. Arch Dermatol 1991;127:995-9.
112. Garbe C, Kruger S, Stadler R, et al. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989;28:517-23.
113. Quaba AA, Wallace AF. The incidence of malignant melanoma (0 to 15 years of age) arising in "large" congenital nevocellular nevi. Plast Reconstr Surg 1986;78:174-81.